Faculty – Medical Affairs & Communications Launch Readiness Summit

Kavita Aggarwal
Vice President, Medical Affairs, DOVA PHARMACEUTICALS

Richa Attre
Associate Director, Publications Management, Medical Affairs, REGENERON PHARMACEUTICALS

Howard Berkowitz
Respiratory and Immunology Medical Science Liaison — U.S. Field-Based Medical Affairs NJ/NYC Region, SANOFI

Howard Dorfman


view speaker profile

Howard L. Dorfman is Founder of H.L. Dorfman Pharmaceutical Consulting, LLC providing compliance, regulatory and risk management consulting services to pharmaceutical and biotech companies and law firms.

His areas of expertise include FDA regulatory law, fraud and abuse, health care compliance, risk management, corporate governance, and litigation.

Mr. Dorfman served as Vice President and General Counsel at Ferring Pharmaceuticals, Inc. in Parsippany, New Jersey where he was responsible for all legal matters relating to the U.S. affiliate of a Swiss-based global pharmaceutical and biotech company. Previously, he served as a Counsel in the Life Sciences group at Ropes & Gray LLP in New York where his practice focused on compliance and regulatory issues relating to the pharmaceutical, biotech, and medical device industries.

Prior to joining Ropes & Gray, Mr. Dorfman was the chief legal officer of the pharmaceutical division of Bayer Healthcare LLC. Before joining Bayer, he was a member of the Bristol-Myers Squibb legal department as Counsel in the Litigation group involved in defense of nationwide product liability litigation and later as Counsel to the US Medicines Group involved in regulatory, compliance and commercial work.

Mr. Dorfman is an adjunct professor at Seton Hall University School of Law and has lectured and published articles on a range of issues including compliance, regulatory and litigation. He is Editor and Contributing Author of the Practising Law Institute Pharmaceutical Compliance and Enforcement Answer Book, now in its fourth edition. He received his B.A. with honors from Yeshiva University and his J.D. degree from Brooklyn Law School.

Lubna Jamal
Real-World Evidence Consultant, PROGENICS PHARMACEUTICALS

view speaker profile

Dr. Jamal has been involved in clinical trials for more than 10 years and is currently consulting for Progenics, Pharmaceuticals. At Progenics, Pharmaceuticals she works with the planning, development, execution and reporting of clinical trials and real world evidence (RWE)/ big data trials. Prior to Progenics, she has for over 4 years of experience in the government and pharmaceutical industry at the national, regional and global levels. Through these experiences, she has built unique expertise in clinical development, and medical affairs in several disease areas. She possesses extensive clinical and scientific knowledge to ensure benchmarks are met in medical and pharmaceutical business environments. A passionate and visionary results-oriented leader with management experience in leading strategic, medical affairs, translational medicine, clinical development, legal, policy, and operations teams.
Dr. Jamal attended Howard University for her undergraduate studies subsequently did research on a collaborative project between Howard University and Johns Hopkins University entitled “Center for Reducing Asthma Disparities” for two years. She graduated from San Juan Bautista School of Medicine Caguas, Puerto Rico with a focus on community health and completed a Public Health Certificate in Maternal and Child Health at George Washington University. Furthermore, she completed a Master of Business Administration at George Washington University.

Daniel Jones
Medical Director and U.S. Lead — M.S. Franchise, Interferons, Opicinumab, EMD SERONO

view speaker profile

Daniel Jones, Ph.D., is Senior Medical Director, Neurology & Immunology at EMD Serono. In his current role, he serves as the US Medical Affairs launch lead for MAVENCLAD (Cladribine Tablets).
Danny joined EMD Serono in January 2018 from Biogen, where he held a number of Medical Director roles of increasing responsibility. Most recently, he served as the Global and US Medical Lead for MS Franchise & Pipeline. Prior to Biogen, Danny was an MSL in epilepsy and movement disorders at Lundbeck, where he served as the field medical lead for Onfi (clobazam).
Danny completed his Ph.D. at UCSF and his postdoctoral fellowship at Duke University Medical Center, where he was awarded grants from NIH and the Epilepsy Foundation; his research has been published in the Journal of Neurophysiology, Nature, and PNAS. He resides in Newton with his wife and four young children.

Barry Lubarsky, Ph.D.
Senior Medical Director, Medical Affairs, ALKERMES

view speaker profile

Barry Lubarsky is currently Senior Medical Director for Medical Affairs at Alkermes, Inc. where he is responsible for medical strategy and launch preparations for a novel drug combination under investigation for the treatment of major depressive disorder. Prior to Alkermes, Barry was at Ocular Therapeutix, Inc. where he led the build-out of the medical affairs group to support a pipeline and launch of innovative ophthalmic therapies. Before Ocular, Barry was at Vertex Pharmaceuticals Incorporated, where he led a medical director group that supported the launches of two personalized genetic medicines for the treatment of patients with cystic fibrosis. Barry also has medical affairs experience in the areas of hemophilia, inflammation, and dermatology. Barry holds a Ph.D. in Biochemistry from Stanford University.

Alison Martens, RN, BSN, CCRP
Medical Science Liaison, Northeast Region and Team Lead, MEDA PHARMACEUTICALS

view speaker profile

Alison Martens began her career as a Neonatal Critical Care Nurse in Hartford, CT. She then moved to the pharmaceutical industry to hold several positions in Marketing and Medical Affairs departments, which included roles in sales, medical communications, research and regulatory. For the past 15 years she has worked as a medical science liaison and team lead in the facilitation of various research projects and the development, dissemination and presentation of medical information to thought leaders and healthcare organizations. Alison obtained her Bachelor of Science in Nursing at the University of Connecticut, and has partially completed a master’s program in management, policy and leadership at Yale University Graduate School of Nursing. She is also a Certified Research Coordinator and licensed for legal promotional material review to maintain compliance with the Office of Prescription Drug Promotion regulations. She has managed the submission, review and oversight of more than 30 investigator-initiated studies evaluating drugs in various clinical settings and preclinical tissue or animal models. Alison currently works with MEDA Pharmaceuticals. Past companies include Boehringer Ingelheim, Sepracor, Baxter Healthcare, Ikaria and Discovery Labs. The majority of Alison’s pharmaceutical involvement has focused on respiratory and cardiovascular therapeutics and devices for the treatment of Asthma, Chronic Obstructive Lung Disease, Allergic Rhinitis, Pulmonary Hypertension and Myocardial diseases.

Scott McConnell
Scientific Affairs Consultant, KALEIDO BIOSCIENCES

Ray Pourfarzib, Ph.D.
Executive Director and TA Medical Lead Metabolics, ALEXION PHARMACEUTICALS

Kanchan Relwani, M.D.
Vice President, Medical Strategy, Medical Affairs, ALKERMES

view speaker profile

Kanchan Relwani, M.D., is currently Vice President Medical Strategy, Medical Affairs for Alkermes Inc. In this role, Kanchan is responsible for the Medical Affairs product strategies, as well as leading the field medical organization. Kanchan is an experienced Medical Affairs leader who has held positions of increasing responsibility, including heading the North American Medical Affairs group at Vertex Pharmaceuticals, and subsequently, leading the Medical Affairs and Clinical Teams at Stallergenes Greer. She has launched multiple products across different therapeutic areas and has a proven track record of leading successful, collaborative, cross-functional teams. Kanchan is an ophthalmologist by training and also has clinical research experience from UCL London, UK, and Harvard Medical School.

Daniel Snyder
Senior Director Medical Affairs, REVANCE THERAPEUTICS

Tyson Tu
Director and Head, Medical Communications, ALKERMES

Irene von Hennigs, Pharm.D.
Executive Director and TA Medical Lead Complement, Hematology and Nephrology, ALEXION PHARMACEUTICALS

Courtney Zeni
Associate Medical Director, Product Development, NOVEN PHARMACEUTICALS

Jenny Zhang
Associate Director, Portfolio and Strategy Launch Lead, Global Medical Affairs — Oncology, EMD SERONO

Steven Zhang
Vice President, Medical Affairs, KALA PHARMACEUTICALS